EDIT News and Press, Editas Medicine Inc. From 03/30/23

2023-03-30 08:45:00 ET There's a lot of excitement around the potential for gene-editing stocks because their therapies have the potential to not only treat diseases, but cure them. One such company is Editas Medicine (NASDAQ: EDIT) . Editas focuses on CRISPR (clustered, reg...

2023-03-17 16:16:22 ET Summary Here's a long list of biopharmas exposed to SVB Financial Group. Many of these deposits will be uninsured. However, since SVB Financial Group was quite solvent otherwise, much of these deposits should be recoverable by these small companies. ...

CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linea Aspesi as the Company’s Executive Vice President and Chief People Officer. Ms. Aspesi will lead Editas’ human ...

Summary If EDIT-101 continues to show positive results, it has the potential to become the first-ever gene-editing therapy approved for a genetic disease. Editas has established collaborations with leading biopharmaceutical companies, including Bristol Myers Squibb and Juno Therapeutics...

Editas Medicine ( NASDAQ: EDIT ) stock rose ~6% on Wednesday after Q4 revenue beat estimates. Q4 net loss widened to -$60.74M, compared to -$41.44M in the year ago period. Collaboration and other research and development revenues declined -47.6% Y/Y to $6.54M, but surpassed an...

Editas Medicine press release ( NASDAQ: EDIT ): Q4 GAAP EPS of -$0.88 misses by $0.08 . Revenue of $6.54M (-47.6% Y/Y) beats by $2.78M . Collaboration and other research and development revenues decreased by $6.0 million to $6.5 million for the three months ended Decem...

Commenced parallel patient dosing in the EDIT-301 RUBY trial for SCD, following clinical proof-of-concept demonstrated last quarter On track to provide clinical update for RUBY trial by mid-2023 and dose 20 total patients by year-end On track to dose first patient in EDIT-301 EDIT...

Editas Medicine ( NASDAQ: EDIT ) is scheduled to announce Q4 earnings results on Wednesday, February 22nd, before market open. The consensus EPS Estimate is -$0.81 (-32.8% Y/Y) and the consensus Revenue Estimate is $3.76M (-69.8% Y/Y). Over the last 1 year, EDIT has beaten E...

CAMBRIDGE, Mass., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, February 22, 2023, at 8:00 a.m. ET to discuss results for the fourth quar...

In stock investing, it's easy to focus on big names and blue-chip companies since they are frequently reported in financial media. Conversely, smaller companies, but with promising businesses, tend to be ignored. The latter have smaller market capitalizations and usually trade at more affordable ...